Bfsg LLC Raises Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Bfsg LLC raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 23.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,363 shares of the company’s stock after purchasing an additional 3,297 shares during the period. Bfsg LLC’s holdings in Elanco Animal Health were worth $255,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Elanco Animal Health in the fourth quarter worth about $368,000. Vanguard Group Inc. lifted its holdings in shares of Elanco Animal Health by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock worth $737,083,000 after acquiring an additional 467,196 shares during the last quarter. Sanders Morris Harris LLC bought a new stake in Elanco Animal Health in the first quarter worth about $6,614,000. Mcdonald Partners LLC bought a new stake in Elanco Animal Health during the 1st quarter valued at about $358,000. Finally, Hedeker Wealth LLC grew its stake in Elanco Animal Health by 6.4% in the first quarter. Hedeker Wealth LLC now owns 82,652 shares of the company’s stock worth $1,346,000 after purchasing an additional 4,995 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Transactions at Elanco Animal Health

In related news, Director Michael J. Harrington acquired 3,500 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now owns 81,094 shares in the company, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The trade was a 200.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Down 3.2 %

Shares of NYSE ELAN opened at $12.84 on Friday. The firm has a fifty day moving average of $14.47 and a 200-day moving average of $14.92. The stock has a market capitalization of $6.35 billion, a PE ratio of -4.85, a P/E/G ratio of 1.53 and a beta of 1.40. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.80. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.18 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Barclays increased their price target on shares of Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Finally, Piper Sandler dropped their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.43.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.